Gilead Sciences Q1 FY25: where the revenue came from and where it went
The whole income statement of Gilead Sciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2025
- Reported
- May 7, 2025
Revenue$6.67B
+0% year over year
Gross profit$5.13B
77% margin
Operating profit$2.24B
34% margin
Net profit$1.32B
20% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 6.67 | 100% | +0% |
| Biktarvy | 3.15 | 47% | +7% |
| Other revenue | 1.24 | 19% | |
| Descovy | 0.59 | 9% | +38% |
| Yescarta | 0.39 | 6% | +2% |
| Genvoya | 0.36 | 5% | −10% |
| Liver disease products | 0.35 | 5% | |
| Veklury | 0.30 | 5% | |
| Trodelvy | 0.29 | 4% | −5% |
| Cost of revenue | −1.54 | 23% | |
| Gross profit | 5.13 | 77% margin | +0pp |
| SG&A | −1.26 | 19% | −2pp |
| Other | −1.63 | 24% | +0pp |
| Operating profit | 2.24 | 34% margin | +98pp |
| Interest & other costs | −0.59 | ||
| Tax | −0.33 | ||
| Net profit | 1.32 | 20% margin | +82pp |
347 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest